The IMI2 Joint Undertaking shall have the following objectives:

1. (a)

   to support, in accordance with Article 25 of Regulation (EU) No 1291/2013, the development and implementation of pre-competitive research and of innovation activities of strategic importance to the Union’s competitiveness and industrial leadership or to address specific societal challenges in particular as described in parts II and III of Annex I to Decision 2013/743/EU, and in particular the challenge to improve European citizens’ health and well-being;

2. (b)

   to contribute to the objectives of the Joint Technology Initiative on Innovative Medicines, in particular to:

   1. (i)

      increase the success rate in clinical trials of priority medicines identified by the World Health Organisation;

   2. (ii)

      where possible, reduce the time to reach clinical proof of concept in medicine development, such as for cancer, immunological, respiratory, neurological and neurodegenerative diseases;

   3. (iii)

      develop new therapies for diseases for which there is a high unmet need, such as Alzheimer’s disease and limited market incentives, such as antimicrobial resistance;

   4. (iv)

      develop diagnostic and treatment biomarkers for diseases clearly linked to clinical relevance and approved by regulators;

   5. (v)

      reduce the failure rate of vaccine candidates in phase III clinical trials through new biomarkers for initial efficacy and safety checks;

   6. (vi)

      improve the current drug development process by providing support for the development of tools, standards and approaches to assess efficacy, safety and quality of regulated health products.